Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAKK 06/14 trial of intravesical VPM1002BC for recurrent non-muscle invasive bladder cancer after prior BCG
NL-OMON45818Phase 2Withdrawn
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Sep 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant BCG in bladder cancer and non-muscle-invasive bladder cancer (NMIBC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoints: Dose limiting toxicity of intravesical VPM1002BC instillations and Recurrence-free rate in the bladder at 60 weeks. Planned start Sep 2016; status: withdrawn.
02
Drugs
recombinant BCG
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON45818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45818.